End of Q3 2020 WinInStocks Portfolio Review

Updated: Nov 17, 2020

Hello fellow traders and my subscribers. Hope you had a profitable week. It was a great week indeed with the Pfizer vaccine giving us a great gap up on Monday morning: S&P 500 up 75 points (+2.1%) this week, Nasdaq closed at 11,829 (-0.6%).

As a norm for the past several months, the future of the market is still a bit shaky, as some of the vaccine hopes are premature in my mind. Also, it is yet unclear what the USA government will do in terms of business support. So, don't put away the big red button with "SELL EVERYTHING" on it just yet.

I decided to start quarterly updates to my portfolio, following the release of the financial reports for the majority of the companies in it. I will continue to do a look at EPS every quarter.

Below is the status of my portfolio, showing unrealized gains/losses and gains for this week.

As usual, you may see this live here: https://www.wininstocks.com/watch-list-and-portfolio

Below is the summary of reported EPS, surprize vs. expectations, and YOY difference vs. Q3 2019:

Most of the stocks performing well. A few misses:

  • PETQ miss was due to one-time write-offs. The company said that it has now reopened all of its locations, so I am expecting a good profit next quarter.

  • GOCO reported a big miss as it decided to give stock options to its employees. Not sure if this is a wise decision given the recent price action and how such moves may be perceived when the company just started. I still have a positive outlook for the company for the next 2 years, but management has to be watched. Management decisions that are unpopular with institutions may cause stock price drops at the moments you least expect them.

The portfolio looks good for YOY growth with the exceptions of a few companies which I bought in hopes they would recover to pre-COVID levels in the next few quarters.

Changes in Positions this week


  • GoHealth, Inc. (GOCO) - Nov 11th

  • Trulieve Cannabis (CNSX:TRUL) - Nov 11th

  • Ichor Holdings, Ltd. (ICHR) - Nov 11th

  • Fulgent Genetics Inc (FLGT) - Nov 12th


  • NBEV @ $2.82 for 65% profit - Nov 11th


Recent Posts

See All

ATNX: way oversold, doubling down here

Doubled down on ATNX at $5.32. The company is down 50% today based on quarterly results and FDA rejection of their drug. However: 1. the company still has room to fight the decision 2. the company has

  • Pinterest
  • Instagram
  • Facebook